Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Diagnostics group Novacyt said its first-half revenue had jumped 50%, underpinned by demand for its Covid-19 tests.
Revenue for the six months through June increased to €94.7 million, up from €63.3 million year-on-year.
The company also announced subsidiary Primerdesign had won a new contract under the UK's PHE National Microbiology Frameworkfor the supply of Covid-19 tests to the National Health Service.
It reiterated full-yeawr revenue guidance of £100 million, excluding revenue from the UK's Department of Health and Social Care, which amounted to $40.8 million in the first half.
'The company expects continued strong growth in private testing as markets and travel re-open and, as the Northern Hemisphere heads into winter, the potential for higher infection rates will increase the need for Covid-19 testing,' Novacyt said.